BRCA1 and cancer: However, concerns remain regarding what consumers may glean about the information these tests convey regarding their inherited risk of cancer.7,14 In March 2018, 23andMe received FDA authorization to market DTC screening limited to the three AJ BRCA1/2 founder mutations.